Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ImClone, Bristol-Myers, Merck KGaA deal

IMCL, BMY and MRK will co-develop and co-commercialize Erbitux cetuximab in Japan, where the chimeric

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE